Patient Engagement in the Era of CAR-T
In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is especially pertinent now that many innovative drug makers are seeking to become much more than just purveyors of pills and expand along the life science continuum, providing positive healthcare outcomes and wellness solutions in place of mere units of product. Perhaps nowhere, though, has real patient centricity been more in evidence than with the new generation of cell and gene-based therapies.
This is largely because with state-of-the-art, biology-based, personalised medicines — such as cell gene and neoantigen therapies — the traditional boundaries separating the patient, the process, and the product are very much blurred. “What really distinguishes treatments such as chimeric antigen receptor T cell therapies is the patient is not just the recipient of a drug product. The patient is the product,” explains Marc Boutin, global head patient engagement at Novartis and former CEO of the US National Health Council. “Patients are truly central to each and every activity as the patient’s own cells are the starting material for all manufacturing processed and, after genetic modification, form the essence of the final material,” he emphasizes.
Marc Boutin – Global Head of Patient Engagement, Novartis
“How are you today?” For patients, this question may be a challenge. Honest answers can stop a conversation straight away. I know what I am talking about. 25 years ago, a series of tragic diagnoses hit my family. Over a short period, all diagnosed loved ones passed…
Rendering CGT Genuinely Patient Centric
In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is especially pertinent now that many innovative drug makers are seeking to become much more than just purveyors of pills and expand along the life science continuum, providing positive healthcare outcomes and wellness solutions in place of mere units of product…
CAR-T and the Art of Managing Expectations
Chimeric antigen receptor (CAR)-T therapy was first approved by the US FDA back in 2017 amid a great deal of fanfare and high expectations among patients about its potential as a revolutionary, perhaps even decisive, new pillar in the war on cancer. Five years later, however, many are still left wondering whether this radically different treatment paradigm can ever become the silver bullet the medical community…
CGT, Real World Evidence & The Patient Experience
One of the enduring conundrums around ground-breaking and potentially paradigm-shifting treatments such as CAR-T is the ever-thorny question of how fast to move them to market when the promise seems so great, but the evidence remains so patchy. So far, top tier regulators such as the US FDA and the European Medicines Agency (EMA) have sought to square the circle by granting speedy access, but under…
Patient Engagement Roundtable: A Varied Global Picture
As complex cutting-edge therapies come online, industry sponsors are increasingly looking to engage with patients, caregivers, and advocacy groups earlier and more broadly in the drug development process to better understand their needs. However, as the below insights from four of Novartis Oncology’s patient engagement leads show, successfully integrating patient voices means different things in different geographies, where language, education, culture, healthcare systems, and economic factors must all be taken into consideration.
Title
Emerging cell and gene therapies herald immense clinical value for patients, society, and healthcare systems: carrying the potential to offer life-changing solutions for people with few or no alternative treatments. Given the limited amount of long-term…
Latest Issue – eBook
Patient Engagement in the Era of CAR-T
eBook
Patient Engagement in the Era of CAR-T
In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is especially pertinent now that many innovative drug makers are seeking to become much more than just purveyors of pills and expand along the life science continuum, providing positive healthcare outcomes and wellness solutions in place of mere units of product. Perhaps nowhere, though, has real patient centricity…
Top Interviews on PharmaBoardroom
Karin Blumer
Read full interviewNicolaus kroger
Read full interviewLorna WarwickRead full interviewKathy Pritchard-JonesRead full interviewNavin PintoRead full interviewClaire SaxtonRead full interview
Previous
Next
See more about Patient Engagement
Novartis: CAR-T’s Journey to Market in Europe
Two years on from the introduction of Novartis Oncology’s CAR-T therapy to Europe, Emnuele Ostuni, the firm’s European head of cell and gene therapy, spoke to…
New Leadership for Novartis Oncology China
Portuguese national Isabel Afonso, a Novartis and Sandoz veteran of almost 20 years, has taken on a new role as general manager of Novartis’ highly strategic oncology franchise in China as of November 2021…
RWE: Unlocking the Full Potential of Cell & Gene
Emerging cell and gene therapies herald immense clinical value for patients, society, and healthcare systems: carrying the potential to offer life-changing solutions for people…
China Enters CAR-T Era with Fosun-Kite Yescarta Approval
A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further developments in the Chinese cell and gene therapy space, as multinationals…
Denmark’s Patient Data Goldmine: 5 Country Managers Have Their Say
Data has been collected within Danish healthcare for more than 40 years, extending beyond the national patient registry to include a broad range of data points, from IVF…
Discover our country reports
Previous
Next
HCLS USAHCLS China InFigures Asia Pacific
HCLS FranceRead full interviewSwitzerlandSingapore
